In the context of the structural complexity necessary for a molecule to selectively display a
therapeutical action and the requirements for suitable pharmacokinetics, a robust synthetic …

Background and Purpose The development of effective therapeutic strategies against
Alzheimer's disease (AD) remains a challenge. I2 imidazoline receptor ligands have a …

Abstract Imidazoline‐2 binding sites (I2BS) exhibit specific expression in reactive astrocytes
of the brain and are implicated in various pathophysiological processes, including …

Recent findings unveil the pharmacological modulation of imidazoline I 2 receptors (I 2-IR)
as a novel strategy to face unmet medical neurodegenerative diseases. In this work, we …

Recent evidence suggests that I2-imidazoline ligands have neuroprotective properties in
animal models of neurodegeneration, such as Alzheimer's disease (AD). We recently …

Imidazoline I 2 receptors (I2-IRs) are altered in Alzheimer's disease (AD) patients and are
associated with analgesia. I2-IRs are not structurally described, and their pharmacological …

Brain aging and dementia are current problems that must be solved. The levels of
imidazoline 2 receptors (I 2-IRs) are increased in the brain in Alzheimer's disease (AD) and …

Abstracts Agmatine is a biogenic amine synthesized following decarboxylation of L-arginine
by the enzyme arginine decarboxylase and exhibits favourable outcome in …

In searching for novel targets to design antidepressants, among the characterized
imidazoline receptors (IR), I2 receptors are an innovative therapeutical approach since they …

Behavioural and psychological symptoms of dementia (BPSD), including fear-anxiety-and
depressive-like behaviour, are present in Alzheimer's disease (AD), together with memory …